Abstract
BackgroundSecukinumab has demonstrated efficacy in moderate to severe plaque psoriasis (PP) by improving the Psoriasis Area and Severity Index (PASI), but patients’ quality of life is not always quantified in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
